{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:40:43Z","timestamp":1760575243596,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejps.2021.105781","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T11:50:16Z","timestamp":1614685816000},"page":"105781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3201-6352","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Lombard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-1903","authenticated-orcid":false,"given":"Hitesh","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-2749","authenticated-orcid":false,"given":"Sonya C.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivelina","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayode","family":"Ogungbenro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105781_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet North Am. Ed."},{"key":"10.1016\/j.ejps.2021.105781_bib0002","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","article-title":"Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics","volume":"27","author":"Claret","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2021.105781_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2021.105781_bib0004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2021.105781_bib0005","first-page":"689","article-title":"Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer","volume":"25","author":"Jang","year":"2013","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.ejps.2021.105781_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000357714","article-title":"Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer","volume":"86","author":"Jang","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.ejps.2021.105781_bib0007","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejca.2008.11.010","article-title":"A simulation study to evaluate the impact of the number of lesions measured on response assessment","volume":"45","author":"Moskowitz","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2021.105781_bib0008","doi-asserted-by":"crossref","first-page":"W64","DOI":"10.2214\/AJR.12.9668","article-title":"RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0","volume":"201","author":"Nishino","year":"2013","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejps.2021.105781_bib0009","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.3928","article-title":"New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejps.2021.105781_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002800000144","article-title":"Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer","volume":"46","author":"Ouellet","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105781_bib0011","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3892\/ol.2013.1424","article-title":"RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma","volume":"6","author":"Ruan","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejps.2021.105781_bib0012","first-page":"4318","article-title":"Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement","volume":"9","author":"Schwartz","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2021.105781_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2016.07.009","article-title":"Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer","volume":"66","author":"Tate","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2021.105781_bib0014","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1158\/1078-0432.CCR-07-4754","article-title":"A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine\u00a0+\u00a0carboplatin in non-small cell lung cancer patients","volume":"14","author":"Tham","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2021.105781_bib0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","article-title":"Population pharmacokinetics of total and unbound plasma cisplatin in adult patients","volume":"57","author":"Urien","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105781_bib0016","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2021.105781_bib0017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bcp.12994","article-title":"Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer","volume":"82","author":"Zecchin","year":"2016","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872100083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872100083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:57:00Z","timestamp":1760529420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872100083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":17,"alternative-id":["S092809872100083X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105781","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105781"}}